ReviewMolecular cancer2025
Advances in engineering immune-tumor microenvironments on-a-chip: integrative microfluidic platforms for immunotherapy and drug discovery.
Review in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Review
- Metabolic rewiring of the dendritic cell-T cell axis: tumour-derived barriers and therapeutic opportunities.Experimental & molecular medicine · 2026Review
- Next-generation skin wound healing related disease models with integration of immune cells.Protein & cell · 2026Review
- 3D Bioprinting for Tumor Microenvironment Reconstruction: Advances, Challenges, and Future Perspectives.Biotechnology journal · 2026Review
- Organoids in cancer therapy: translational applications and clinical promise.Molecular cancer · 2026Review
- What Is-and What Is Not-Immunogenic Cell Death? Functional Definitions, Experimental Standards, and Common Pitfalls.International journal of molecular sciences · 2026Review
- Application and prospects of organoid-on-a-chip in research on the intestinal mucosal barrier.Burns & trauma · 2026Review
- 3D Bioprinting Strategies in Autoimmune Disease Models.International journal of molecular sciences · 2025Review
- AI-Integrated Micro/Nanorobots for Biomedical Applications: Recent Advances in Design, Fabrication, and Functions.Biosensors · 2025Review
- From Cells to Organoids: Approaches, Regulatory Mechanisms, Applications, and Challenges of Organoids.Cells · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The design and application of microfluidic immune system-on-a-chip (ISOC) technology have played a critical role in cancer immunology and drug discovery over the past decades. The system provides a highly controlled and physiologically relevant platform for studying immune responses and therapeutic interventions. Emerging trends in 3D bioprinting, organoid fusion, and multi-organ systems-on-a-chip further expand the capabilities of ISOC by enabling systemic immune interactions and modeling of the tumor microenvironment. Despite these advances, scalability, standardization, and long-term immune cell viability remain significant challenges that must be addressed to fully harness the potential of ISOC in clinical applications. Overall, ISOC represents a transformative tool in cancer research, offering innovative solutions for immunotherapy trials, biomarker discovery, and precision medicine. Therefore, in this study, the role of ISOC in cancer immunotherapy was investigated, focusing on its ability to recapitulate primary and secondary immune functions, model immune-tumor interactions, and enhance screening and optimization of immune-based therapies. Device design and modeling strategies were also discussed, demonstrating how ISOC platforms simulate dynamic immune cell activity, cytokine signaling, and antigen presentation to improve drug efficacy assessments. The application of ISOC technology in drug discovery and its potential to accelerate clinical trials and develop personalized immunotherapy were further explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.